Research programme: protein degradation-based therapeutics - Arvinas

Drug Profile

Research programme: protein degradation-based therapeutics - Arvinas

Alternative Names: ARCC-29; ARV-110; ARV-771; BET-PROTAC ARV-771; Hydrophobic Tagging small molecules - Arvinas; HyT small molecules - Arvinas; PROTAC ARV-771; PROTAC ARV-825; PROTACs - Arvinas; Protein-targeting chimeric molecules - Arvinas; Proteolysis Targeting Chimeric molecules - Arvinas

Latest Information Update: 14 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Arvinas
  • Developer Arvinas; Yale University
  • Class Anti-inflammatories; Antineoplastics; Small molecules
  • Mechanism of Action Androgen receptor degradation enhancers; BRD4-protein-inhibitors; Bromodomain and extraterminal domain protein inhibitors; Proteasome stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Breast cancer; Haematological malignancies; Prostate cancer; Solid tumours
  • Research Autoimmune disorders; Inflammation

Most Recent Events

  • 08 Dec 2017 Pharmacodynamics data from preclinical trials in Breast cancer released by Arvinas
  • 21 Nov 2017 Arvinas and Macroceutics agree to co-develop protein degraders
  • 15 Nov 2017 Arvinas expands its license agreement with Genentech for the development of protein degradation-based therapeutics using Arvinas' novel PROTAC technology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top